Curanex Pharmaceuticals Inc Common Stock
NASDAQ: CURX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jun Liu
- Headquarters
- Jericho, United States
- IPO year
- 2025
- Market cap
- $7.5M
- Website
- https://www.curanexpharma.com
Loading CURX…
Loading profile data…Frequently asked questions about CURX
What does Curanex Pharmaceuticals Inc Common Stock (CURX) do?
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis...
Where does CURX trade?
Curanex Pharmaceuticals Inc Common Stock (CURX) trades on the NASDAQ Global Select.
What sector is CURX in?
Curanex Pharmaceuticals Inc Common Stock (CURX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Curanex Pharmaceuticals Inc Common Stock?
Jun Liu is the chief executive officer of Curanex Pharmaceuticals Inc Common Stock (CURX).
Where is Curanex Pharmaceuticals Inc Common Stock headquartered?
Curanex Pharmaceuticals Inc Common Stock is headquartered in United States.
Does CURX pay a dividend?
Curanex Pharmaceuticals Inc Common Stock (CURX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CURX go public?
Curanex Pharmaceuticals Inc Common Stock (CURX) completed its initial public offering in 2025.